



GPCRomics of Homeostatic and Disease-Associated Human Microglia

Cheng-Chih Hsiao^{1,2*}, Roman Sankowski³, Marco Prinz^{3,4,5}, Joost Smolders^{2,6}, Inge Huitinga^{2,7} and Jörg Hamann^{1,2*}

OPEN ACCESS

Edited by:

Amanda Sierra, Achucarro Basque Center for Neuroscience, Spain

Reviewed by:

Angela Schulz, Leipzig University, Germany Marta Olah, Columbia University Irving Medical Center, United States

*Correspondence:

Cheng-Chih Hsiao c.hsiao@amsterdamumc.nl Jörg Hamann j.hamann@amsterdamumc.nl

Specialty section:

This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the journal Frontiers in Immunology

Received: 28 February 2021 Accepted: 22 April 2021 Published: 14 May 2021

Citation:

Hsiao C-C, Sankowski R, Prinz M, Smolders J, Huitinga I and Hamann J (2021) GPCRomics of Homeostatic and Disease-Associated Human Microglia. Front. Immunol. 12:674189. doi: 10.3389/fimmu.2021.674189 ¹ Department of Experimental Immunology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, Amsterdam, Netherlands, ² Neuroimmunology Research Group, Netherlands Institute for Neuroscience, Amsterdam, Netherlands, ³ Institute of Neuropathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁴ Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany, ⁵ Center for Basics in NeuroModulation (NeuroModulBasics), Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁶ MS Center ErasMS, Departments of Neurology and Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ⁷ Swammerdam Institute for Life Sciences, Center for Neuroscience, University of Amsterdam, Amsterdam, Netherlands

G-protein-coupled receptors (GPCRs) are critical sensors affecting the state of eukaryotic cells. To get systematic insight into the GPCRome of microglia, we analyzed publicly available RNA-sequencing data of bulk and single cells obtained from human and mouse brains. We identified 17 rhodopsin and adhesion family GPCRs robustly expressed in microglia from human brains, including the homeostasis-associated genes CX3CR1, GPR34, GPR183, P2RY12, P2RY13, and ADGRG1. Expression of these microglial core genes was lost upon culture of isolated cells ex vivo but could be acquired by human induced pluripotent stem cell (iPSC)-derived microglial precursors transplanted into mouse brains. CXCR4 and PTGER4 were higher expressed in subcortical white matter compared to cortical grey matter microglia, and ADGRG1 was downregulated in microglia obtained from normal-appearing white and grey matter tissue of multiple sclerosis (MS) brains. Single-cell RNA sequencing of microglia from active lesions, obtained early during MS, revealed downregulation of homeostasis-associated GPCR genes and upregulation of CXCR4 expression in a small subset of MS-associated lesional microglia. Functional presence of low levels of CXCR4 on human microglia was confirmed using flow cytometry and transwell migration towards SDF-1. Microglia abundantly expressed the GPCR down-stream signaling mediator genes GNAI2 (α_{i2}), GNAS (α_s), and GNA13 (α_{13}), the latter particularly in white matter. Drugs against several microglia GPCRs are available to target microglia in brain diseases. In conclusion, transcriptome profiling allowed us to identify expression of GPCRs that may contribute to brain (patho)physiology and have diagnostic and therapeutic potential in human microglia.

Keywords: brain, microglia, GPCRs, G proteins, system biology, multiple sclerosis, CXCR4

INTRODUCTION

Microglia are brain-resident phagocytic cells that contribute to brain homeostasis as well as disease (1, 2). Populating the central nervous system (CNS) during embryonic development, microglia persist for the rest of life through local self-renewal. As a consequence, they possess a unique transcriptional signature that emerged only recently from RNA sequencing (RNAseq) of purified primary cells (3). Notably, G protein-coupled receptors (GPCRs) figure prominently in the microglia transcriptome, as exemplified by the characteristic surface expression of CX3CR1, GPR34, GPR183, P2Y12, P2Y13, and GPR56 (3, 4). GPCRs are the senses of our cells, comprising the largest and most diverse superfamily of membrane proteins in eukaryotic cells. Of particular interest is their widespread cellular distribution and the fact that $\sim 30\%$ of all currently approved pharmaceuticals target them (5). GPCRs control cell and tissue physiology by regulating signaling pathways via heterotrimeric G proteins, which modulate cellular levels of second messengers and, in turn, a wide array of functional activities in all types of cells (6). Microglial GPCRs have been implicated in control of axon outgrowth and cortical laminar positioning during development as well as in support of survival of neurons (CX3CR1), in plasticity (P2Y₁₂) and complement-mediated pruning (C3AR1 and C5AR1) of synapses, in microglial brain colonization (CXCR4) and chemotaxis of microglia to injury (P2Y₁₂), and in neuropathic pain response (P2Y₁₂) (7). Exploring bulk and single cell RNAseq studies of microglia from mice and human, we here describe the expression of GPCR and G protein genes in relation to microglia homeostasis, location, health, and disease.

METHODS

RNAseq and Microarray Datasets

Genome-wide gene expression data of microglia, macrophages, and non-phagocytic cells were derived from various publicly available RNAseq data sets (**Table 1**). Numbers indicating gene

TABLE 1 | RNAseq datasets analyzed in this study

expression are provided either as absolute counts, presenting fragments per kilobase of transcript per million mapped reads (FPKM) or transcripts per kilobase million (TPM), or as relative counts, related to arbitrary chosen, fixed thresholds of all genes in the gene set (e.g., the top 50% = 0.50 percentile). Heatmaps show gene expression intensity, based on the average of all genes, with white indicating low expression and red indicating high expression. *t*-distributed stochastic neighbor embedding (*t-SNE*) plots of the clusters of microglia were generated as described (15). Relative RNA expression levels for *CXCR4* and *CXCL12* from laser-dissected tissue from mixed active/inactive and inactive demyelinated lesions were obtained from a microarray dataset (18).

Flow Cytometry

Isolated human microglia from corpus callosum and subcortical white matter and occipital cortex grey matter were isolated and stained as described (4) with APC-conjugated anti-CD11b (clone ICRF44; eBioscience, San Diego, CA, USA), Alexa 700-conjugated anti-CD14 (clone M φ P9; BD Biosciences, San Diego, CA, USA), PerCP-Cy5.5-conjugated anti-CD15 (clone HI98; BioLegend, San Diego, CA, USA), BB515-conjugated anti-CD45 (clone HI30; BioLegend), PE-Cy7-conjugated anti-CXCR4 (clone 12G5; BioLegend), and PE-conjugated anti-P2Y₁₂ (clone S16007D; BioLegend). Dead cells were visualized by fixable viability dye eFluor 780 (eBioscience). Background staining was determined using fluorescence minus one control. Membrane protein expression was measured on a FACSCanto II (BD Biosciences), and median fluorescence intensity was determined with FlowJo software version 10.1 (Ashland, OR, USA).

Transwell Migration

Human brain microglia and paired peripheral blood monocytes were separately isolated by CD11b and CD14 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) as described (19). 2×10^5 cells were loaded in a volume of 100 µl RPMI1640 medium containing 0.3% bovine serum albumin on transwell filters with a pore size of 5 µm (Corning, Corning, NY, USA).

Species	Cells	Dataset	Reference
arious	microglia	bulk RNAseq of isolated cells from cortex (GM) (human) or whole brains (mouse)	Geirsdottir et al. (8)
uman	brain lysate, microglia	bulk RNAseq of isolated cells from cortex (GM)	Galatro et al. (9)
uman	microglia	bulk RNAseq of isolated cells from cortex (GM)	Gosselin et al. (10)
iuman	microglia	bulk RNAseq of isolated cells from corpus callosum (WM) and occipital cortex (GM) of control and MS donors	Van der Poel et al. (4)
uman	microglia	bulk RNAseq of isolated cells from corpus callosum (WM) and occipital cortex (GM) of control donors	Mizee et al. (unpublished data)
nouse	various	bulk RNAseq of (isolated cells from) whole brains (neurons, oligodendrocytes, astrocytes, and microglia)	Zhang et al. (11)
iouse	microglia, macrophages	bulk RNAseq of isolated cells from whole organs	Van Hove et al. (12)
uman	iPSC-derived iMPs	bulk RNAseq of isolated cells transplanted into the brain of neonatal mice in vivo or cultured in vitro	Svoboda et al. (13)
iouse	microglia	single cell RNAseq of cells from brains of 5XFAD mice	Keren-Shaul et al. (14)
uman	microglia	single cell RNAseq of cells from cortical (GM) biopsies of active MS lesions	Masuda et al. (15)
uman	microglia	single cell RNAseq of cells from cortical (GM) surgically resected brain tissue	Olah et al. (16)
uman	microglia	bulk RNAseg of isolated cells from cerebral cortex (GM)	Olah et al. (17)

WM, white matter; GM, grey matter.

100 ng/ml SDF-1 (stromal cell-derived factor-1, CXCL12) was added as chemoattractant to the lower compartment. After 4 h incubation at 37°C, cells in the lower compartment were harvested and quantified by flow cytometry at a fixed high speed for 120 sec.

Statistics

All analyses were performed in GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA). When data were not normally distributed, non-parametric tests, either Wilcoxon or Mann-Whitney U, were performed.

RESULTS

Species and Cell Type Specificity of GPCR and GPCR Signaling Molecule Expression in Microglia

To explore the presence of GPCRs in microglia, we utilized the list of GPCRs not involved in olfaction, taste, light perception, and pheromone signaling as provided by the International Union of Basic and Clinical Pharmacology (IUPHAR)/British Pharmacological Society (BPS) Guide to Pharmacology (https://www.guidetopharmacology.org) (20). According to the GRAFS classification (21), the 384 receptors comprise 303 rhodopsin, 33 adhesion, 22 glutamate, 15 secretin, and 11 frizzled family members.

To identify GPCR genes that are reliably expressed in human microglia, we first tested bulk RNAseq expression data of homeostatic microglia from different vertebrate species we recently published (8). We found 83 GPCR genes in the top 50% (0.5 percentile) of all genes in the human and/or mouse gene sets (Figure 1A). 42 of these genes were lowly expressed (0.5-0.67 percentile), 12 genes were medium expressed (0.68-0.85 percentile), and 29 genes belonged to the highly expressed genes (0.86-1.0 percentile). While the homeostatic microglia marker genes CX3CR1, GPR34, GPR183, P2RY12, P2RY13, and ADGRG1 (encoding GPR56) were highly expressed in both species, expression of other GPCR genes was medium, low, or even absent in either human or mouse. For example, transcription of ADGRE1, encoding F4/80 in mouse, was lacking in human microglia, in line with its exclusive expression in human eosinophils (22). Other genes with a restricted, high expression in either mouse or human microglia were CCR6, GPR84, GPR146, and FPR1, respectively. Notably, ADGRE5 (encoding CD97), which is abundantly expressed by all types of bone marrowderived leukocytes (23) was lowly expressed in mouse and human microglia, in line with previous findings (24). The previously disputed gene ADGRB1 (encoding BAI1) (25) was undetectable in mouse and human microglia.

We confirmed the list of well-expressed human microglia GPCR genes in four other bulk RNAseq studies of primary human microglia [(4, 9, 10) and Mizee et al, unpublished data]. We found 15 genes abundantly expressed across the different data sets, which formed, together with two genes with a medium expression in grey matter microglia but high expression in white matter microglia (see below), the core microglia GPCR gene set

for our further analyses (for all other genes, see the supplementary information). This gene set comprises rhodopsin (e.g., adenosine, chemokine, complement peptide, lysophospholipid, purinergic, and orphan receptors) as well as adhesion, but not secretin, glutamate, or frizzled family members. Among the 17 selected genes were the homeostatic microglia marker genes *CX3CR1*, *GPR34*, *GPR183*, *P2RY12*, *P2RY13*, and *ADGRG1*.

We next tested the expression of microglial GPCRs in other cell types of the CNS. The three most highly expressed genes, *ADGRG1, P2RY12*, and *CX3CR1*, also appeared top-abundant in whole brain tissue (10) (**Figure 1B**). All selected genes were more abundantly expressed in pure microglia as compared to the whole human cortex, which was further corroborated by data on gene expression in the major cell types of the mouse CNS (11) (**Figure 1C** and **Supplementary Table 1**). Except for *Cxcr4*, expression in microglia was higher as compared to neurons, astrocytes, and oligodendrocytes. Interestingly, high expression in microglia regularly correlated with gene activity in oligodendrocytes, albeit at a lower level.

Next to parenchymal microglia, the CNS harbors borderassociated macrophages with distinct transcriptional signatures, residing in the dura mater, subdural meninges, and choroid plexus (12). Most microglia GPCRs were expressed also in nonparenchymal macrophages of the CNS, at comparable, higher, or lower level (**Figure 1C** and **Supplementary Table 1**). Inclusion of tissue-resident macrophages from peritoneum, lung, and liver unveiled similar patterns (12). The signature genes *Cx3cr1*, *Gpr34*, *P2ry12*, *P2ry13*, and *Adgrg1* were particularly expressed in microglia.

Upon ligation, GPCRs diversify downstream signaling through four main classes of G α subunit – G α_s , G $\alpha_{i/o}$, G $\alpha_{q/11}$, and G $\alpha_{12/13}$ (6). Moreover, G protein-coupled receptor kinases (GRKs) phosphorylate intracellular domains of GPCRs and function together with β -arrestin to regulate the GPCR desensitization (6). Human and mouse microglia expressed *GNA12* (G α_{i2}), *GNAS* (G α_s), *GNA13* (G α_{13}), *GRK2*, and *ARRB2*. In addition, mouse microglia also expressed *Gna15* (G α_{15}) (**Figure 1C** and **Supplementary Table 1**). *Gnai2*, *Gna15*, *Grk2*, and *Arrb2* were higher expressed in microglia as compared to neurons, astrocytes, and oligodendrocytes, while *Gnas* and *Gna12* were expressed in different cell types. G protein, GRK, and β -arrestin gene expression levels in macrophages inand out-side the CNS were mostly comparable.

Regional and Disease Specificity of GPCR and GPCR Signaling Molecule Expression in Human Microglia

Dissected from their natural microenvironment, microglia change their transcriptional program and alter morphological and functional characteristics (10, 19). Indeed, expression of *ADORA3*, *ADRB2*, *CXCR4*, *CX3CR1*, *GPR34*, *LPAR5*, *LPAR6*, *P2RY12*, *P2RY13*, and *ADGRG1* was strongly downregulated or even lost in microglia cultured *ex vivo* for 1 or 7 days (**Figure 2** and **Supplementary Table 2**).

Human induced pluripotent stem cells (iPSCs) can be differentiated into induced microglial precursors cells (iMPs)

$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} $															
Human microglia (percentile) Human microglia (percentile) Zanaty Zanaty <thzanaty< th=""> <thzanaty< th=""> <thzanaty<< td=""><td>A 1.0 GF 0.9 -0.0 -</td><td>CYSLTR1 CCR5 P2RY6 DGRE1 TPRA1 R84 GPR137 GPR155 CCR6 GPR137 GPR107C3AF GPR146 ADRB1 CMKLR1 AL GABBR1 C5AR2 CC C5AR1 C5AR1</td><td>P2RY12 P2RY13 ADGRG1 ADORA3 T PTAFR DRB2 R1 LPAR5</td><td>1</td><td></td><td>Huamn brain lysate (percentile)</td><td>).9-).8-).7-).6-</td><td></td><td></td><td>•</td><td>-</td><td>-</td><td>ADR</td><td>CR4 183 182 F PTGEF</td><td>P2RY CX3C GPR3 GPR3 LPAR LPAR ADOR C3AR C3AR C3AR1 C5AR1 C7AFR CCR1</td></thzanaty<<></thzanaty<></thzanaty<>	A 1.0 GF 0.9 -0.0 -	CYSLTR1 CCR5 P2RY6 DGRE1 TPRA1 R84 GPR137 GPR155 CCR6 GPR137 GPR107C3AF GPR146 ADRB1 CMKLR1 AL GABBR1 C5AR2 CC C5AR1 C5AR1	P2RY12 P2RY13 ADGRG1 ADORA3 T PTAFR DRB2 R1 LPAR5	1		Huamn brain lysate (percentile)).9-).8-).7-).6-			•	-	-	ADR	CR4 183 182 F PTGEF	P2RY CX3C GPR3 GPR3 LPAR LPAR ADOR C3AR C3AR C3AR1 C5AR1 C7AFR CCR1
Family Subfamily Gene M N 0 0 0 1 4 7 1 22 5 6 10 28 4 Khodopsin Adenosine receptor Adrb2 4 0 0 1 47 5 58 143 1248 4227 37 15 28 4 Adrenoceptor Adrb2 4 0 0 1 47 68 35 0 2 8 9 65 344 429 342 147 16 13 240 66 10 2 2 8 9 655 344 429 427 15 124 1240 13 10 10 135 8867 3155 288 136 130 13 1420 667 135 134 1420 13 124 1240 135 134 1240 135 124 1240 135 124 124			.0				U								U
Family Subfamily Gene V	П			numan microgita (percentite)											
c No No <th< td=""><td></td><td></td><td></td><td></td><td></td><td>-</td><td></td><td></td><td></td><td></td><td>Van</td><td></td><td>et al,</td><td></td><td></td></th<>						-					Van		et al,		
RhodopsinAdenosine receptorAdora30001476112225610284AdrenoceptorAdrb24001103256883181501652492038472164Chemokine receptorCcr1300160351434968224331429442737Cx2r4835002896153444921091522Cx3cr11510101015528134527598414117812Class A OrphanGpr34131010109552103421249635110112198427Complement petide receptorC3ar1800210043956372066694681630Cysophospholipid receptorFpr10001137815112810312704835Formylpetide receptorFpr100011378351230736387351287P2Y receptorP2ry122611230930120973736325937315245259433Gar proteinalpha iGna16na2153442201632755542<						Gli	al ce	lls		Bra	ain m	ас	Perip	heral	mac
RhodopsinAdenosine receptorAdora300146112225610284AdrenoceptorAdrb240011032568831813501652492038472164Chemokine receptorCcr1300160351434968224331429442737Cxcr483500160351434968424331429442737Cxcr483500160351434968424331429442737Cxcr4835001101015528113410101521Class A OrphanGpr34131001010155551103421481630Complement petide receptorC3ar1800113781511281081102129Lysophospholipid receptorFpr10001113783512033183735318128P2Y receptorP2ry12261112555415254353756543537565435575543545543545545545545545545545545545545545545	C Family	Subfamily	Gene	Whole cortex	Neuron	Astrocyte	Oligodentrocyte	Microglia	Microglia	MHCII ^{high} dural mac	MHCII ^{Iow} dural mac	Choroid plexus mac	Peritoneal mac	Lung mac	Liver mac
AdrenoceptorAdrh2A0011032568.1815016209.03.472.164Chemokine receptorCcr13001603514.424.334.234.233.22Cxcr483502896.553.444.92109.152.22Cx3cr115100121083.151.04109.152.134Class A OrphanGpr34300210881112.1792.9231.0011.01.0Complement peptide receptorC3ar17000113.851.6691.1771.0011.012												-			
Chemokin ecceptorCcr1·3·0·0·1·60·31·430·642·433·1428·427·3<Cxcr4·8·35·0·2·8·15·16·16·17·12	niedopsin														
Cxcr4835028961534449210915243Cx3cr115161616161616165165164165165164161616Class A OrphanGpr341310				3											
Class A OrphanGpr3413101081581321240673152121Gpr1833000210430533720610121010Complement peptide receptorC3ar18000108112743293210131102102101Formylpeptide receptorFpr100000111037836020810111021203Lysophospholipid receptorLpar50000118403360360360363360363360363363363363364363365365364363365366363365366363365366363365366363365366363365363<				8	35	0	2	8	9	615	344	492	10	915	22
Gpr183300210430533720660461610Complement peptide receptorC3ar180018101			Cx3cr1	15	1	0	13	490	93867	31545	27598	41414	17	8	124
Complement peptide receptorC3ar180021002170293210101012110<		Class A Orphan	Gpr34	13	1	0	10	157	35152	10342	12402	6735	15	281	23
C5ar17000198396166621871117910217041021270Formylpeptide receptorFpr100 <t< td=""><td></td><td></td><td>Gpr183</td><td>3</td><td>0</td><td>0</td><td>2</td><td>190</td><td>4390</td><td>5363</td><td>7206</td><td>6691</td><td>468</td><td>16</td><td>30</td></t<>			Gpr183	3	0	0	2	190	4390	5363	7206	6691	468	16	30
Formylpeptide receptor Fpr1 0<		Complement peptide receptor	C3ar1	8	0	0	2	108	8111	27479	25932	19051	10112	19	8427
Lysophospholipid receptorLpar500009743793013201718175282Lpar6514184933395340269387355127P2Y receptorP2ry1226112533093045264961338273963254412P2ry1380176737750114916528358760Platelet-activating factor receptorPtgr410106371799574414932352934713AdhesionGAdgrg176332755447231748555000361Gα proteinalpha qGnai33325102192184512446924653436Gnai33325528528528528528528alpha qGnag3442101699324875535010817535631631531631531531563156alpha 12/13Gnai4282552852852852866112720735535735631631631631631631631631631631631631			C5ar1	7	0	0	1	98	3965	16696	21873	11177	9108	21700	4935
Lpar651418493339534026938735128P2Y receptorP2ry1226111253009304526496133827385342345P2ry138017673776703775401299106528358360Platelet-activating factor receptorPtgr4101016370144950552455420Prostanoid receptorPtgr4101016371799541410932352934713AdhesionGAdgrg1763327554472337485550070361Gα proteinalpha iGnai33325102192184512446924653436Gnai333255285285285285361362363361Gnai333255285285285285361362363361362363Gα proteinalpha qGnai3332552852852836136337135337612933761353376135337613533761353376135337			-	0	0	0	0	1	1	378	1561	288	1063	14012	12786
P2Y receptor P2ry12 P2		Lysophospholipid receptor	Lpar5	0	0	0	0	9	746	379	301	320	1718	175	282
P2ry13801726787735401028947652835876Platelet-activating factor receptorPtgfr2001967001491005752455420AdhesionGAdgrg176332755447231748555050505050G α proteinalpha iGnai21506620134515015016021021624024052445<				5	1	4			_		3460				
Platelet-activating factor receiptPtdfr200196700144910057352455421AdhesionGAdgrotPtger410101010101907141913552141392359234131AdhesionGAdgrot76070327554172337248551009171311001011		P2Y receptor	-	26	1	1	25	330	93304	5264	9613		396		
Prostanoid receptorPtger410101709741410323293473AdhesionGAdgra1763327554472337745485500700361G α proteinalpha iGnai21506520133251021213485244719212465244524452446G α proteinalpha qGnai33325102190149332165343343G nai12825502850284102157755533701255446AdhesionGnai1282550285028644157755533701255446AdhesionGnai1282930202110021101722293430701215446AdhesionGnai1282555285028293413903216316916AdhesionGnai128293010101010172229343020321810310			-	8	0	1	7	267		5401	10289	4917	65	2835	8736
AdhesionGAdgrq176332755447233748685500970361Gα proteinalpha iGnai2100332510214824322449240224652445Gnai333251021921582432249721682360214962633438alpha qGnai128255328644157755533701259447Gna151001101724229043021782178488289321784882893217848828932103216821682175316916alpha s alpha 12/13Gna123020505051361612105131093217531521782178217821782178218821782188217821882198219821782198219821782188219821782188219821782188219821782188219821782188219821882198				2	0	0	1	96		1449	1809	578	524	55	42
Gα protein alpha iGnai21506620133458148325493249719222266244524421Gnai33325102192154124692301244625343alpha qGnaq34421016993218722126106817751356916Gna11282552864157795533701259447Gna151001101724229043092708187221781868826alpha s alpha 12/13Gna123020101081081209120941030521753152101GRKSGrk2332621810168120912094411209201032552178GRKSGrk233262181046086997944167022591108		a to be determined and be an end to an end	-				_								
Gnai3 33 25 10 21 9 218 410 240 240 343 alpha q Gnaq 34 42 10 16 9 32 1872 108 1775 136 916 Gna1 34 42 10 16 9 921 1872 108 1775 136 916 Gna1 12 0 1 10 124 57 533 701 25 447 Gna15 1 10 12 10 1243 1249 430 1275 136 1276	-			_	_	_	_								
alpha q Gnaq 34 42 10 5 9 932 1872 126 108 135 135 136 13	Gα protein	i alpha i		_											
Gna11 28 25 5 26 41 557 755 533 701 259 447 Gna15 1 0 1 0 1 101 722 290 300 270 2753 1359 2103 alpha s Gna12 30 20 10 108 101 1209 1209 1309 21753 1359 2103 Gna12 30 20 10 108 108 1020 1209 1209 1209 3059 315															
Gna15 1 0 0 1 10 722 290 430 270 278 186 826 alpha s Gna3 477 494 97 364 341 1263 1503 1513 1093 22753 1359 1053 alpha 12/13 Gna12 30 20 10 108 101 120 1258 661 1297 3053 GRKS Grk2 33 26 2 18 102 120 1208 1208 1209 1208 1209 1208 1209 1208 1209 1208 1209 1208 1209 1208 1209 1208 1209 1208 1209 1208 1209 1208 1209 1208 1209 1208 1209 1208 1209 1208 1209 1208 1209 1208 1209 1208 1209 1208 1208 1208 1208 1208 1208 1208 1208 1208 1208 1208 1208 1208 1208 1208 1208		alpha q													
alpha s alpha 12/13Gnas477494973643411263150815131093227531359421033Gna12302010108101081046018112012568661412073005Gna132416371256326239984121932235123522758GRKsGrk2332621810460586929974415670252691103															
alpha 12/13 Gna12 30 20 10 108 104 6018 1120 12568 6614 1297 2070 3055 Gna13 24 16 37 12 56 3262 3998 4152 1932 2391 2352 2758 GRKs Grk2 33 26 2 18 109 4605 8692 9972 4415 6702 5269 11039							_						_		
Gna13 24 16 37 12 56 3262 3998 4152 1932 2391 2352 2758 GRKs Grk2 33 26 2 18 109 4605 8692 9972 4415 6702 5269 11039						_									
GRKs Grk2 33 26 2 18 109 4605 8692 9972 4415 6702 5269 11039		alpha 12/13													
Arrestin β-arrestin Arrb2 19 26 3 14 199 4274 8086 8073 5143 8830 2408 6376		a													
	Arrestin	β-arrestin	Arrb2	19	26	3	14	199	4274	8086	8073	5143	8830	2408	6376

FIGURE 1 | Identification of GPCR and GPCR signaling molecule genes expressed in microglia. (A) Scatter plot providing GPCR gene expression in microglia isolated from human and micre as percentile of all human/mouse genes (8). (B) Scatter plot providing GPCR gene expression in brain and microglia of human as percentile of all genes (10). (C) Expression of GPCR and GPCR signaling molecule genes in mouse cortical tissue, neurons, astrocytes, oligodendrocytes, and microglia (11), and in mouse microglia, non-parenchymal brain and peripheral tissue macrophages (12). Expression is provided as FPKM (11) and gene count (12), respectively. mac, macrophages.

showing the characteristic morphology and gene expression of primary human microglia (13). Notably, iMPs expressed the GPCRs typically found in microglia. When transplanted into the brains of NOD scid gamma (NSG) mice, carrying the human transgenes encoding IL-3, SCF, GM-CSF, and CSF1, expression of *ADRB2, CX3CR1, GPR183, FPR1, LPAR5, LPAR6, P2RY12, P2RY13*, and *ADGRG1* was further enhanced at day 10 and/or 60 (**Figure 2** and **Supplementary Table 2**). This induction was not seen in iMPs cultured for the same period *in vitro*, which rather resulted in a downregulation of the expression of several GPCRs.

Various studies have established regional differences in microglia gene expression (2). Using data from our laboratory, we compared GPCR expression between human microglia obtained from subcortical white and cortical grey matter (4) (**Figure 2** and **Supplementary Table 2**). We found seven genes \geq 2-fold higher expressed in either white or grey matter, respectively. In a second, independent dataset, we could confirm a higher gene expression in white matter microglia for *CXCR4* and *PTGER4* (Mizee et al, unpublished data). Single cell RNAseq has facilitated the investigation of microglial heterogeneity within brain regions. A study addressing this question showed,

with the exception of *C3AR1*, a similar activity of GPCR genes in cortical microglia subsets (16) (**Supplementary Figure 1**).

Changes in gene expression in mouse models for Alzheimer's disease and amyotrophic lateral sclerosis (ALS) have led to the description of a phenotype referred to as disease-associated microglia, associated with significantly reduced expression of several signature GPCR genes (14). When comparing gene expression in pure microglia from normal-appearing, non-lesional tissue of deceased multiple sclerosis (MS) autopsy cases and tissue of non-pathological brains (**Figure 2** and **Supplementary Table 2**), we found downregulation of *ADGRG1* in both, white and grey matter, while expression of other GPCR genes was not changed.

Single cell RNAseq data of (models of) Alzheimer's disease, ALS, and MS revealed that pathological reprogramming only occurs in small subsets of disease-associated microglia that coexist with large subsets of homeostatic microglia and small subsets of infiltrating monocytes (14–16). Notably, disease-associated microglia in lesion biopsies of patients with histologically confirmed early active MS pathology showed reduced expression of the core signature genes *CX3CR1*, *GPR34*, *GPR183*, *P2RY12*, *P2RY13*, and *ADGRG1* (15, 26) (**Figures 3A, B**).

			Gosselin et al, 2017		Svoboda et al, 2019					Van der Poel et al, 2019				
			Μ	icrogl	ia	iMPs	in v	ivo	in vi	tro	W	М	GN	Л
Family	Subfamily	Gene	0 d	1 d	7 d		10 d	60 d	10 d	60 d	CON	MS	CON	MS
Rhodopsin	Adenosine receptor	ADORA3	162	11	46	22265	4864	23998	30578	20433	4359	3640	4780	4124
	Adrenoceptor	ADRB2	86	2	2	2274	1381	8628	1495	673	5246	4813	2837	2975
	Chemokine receptor	CCR1	125	92	188	11746	4952	14665	14118	7546	2840	2712	5234	3877
		CXCR4	111	21	8	2141	90	293	8542	1841	15831	17984	1449	5984
		CX3CR1	920	4	2	5008	74358	346492	146	2243	9175	12011	19974	22293
	Class A Orphan	GPR34	542	26	57	44970	32383	106441	47660	37619	5318	5089	6863	6563
		GPR183	139	44	84	3199	5383	19006	1018	1841	14883	13521	2913	4397
	Complement peptide receptor	C3AR1	222	86	242	15484	9734	18585	24888	25134	6653	5580	6517	6158
		C5AR1	108	346	360	3273	483	1840	5131	7335	7527	8141	2089	2427
	Formylpeptide receptor	FPR1	394	65	323	8478	2127	27248	7967	2325	3730	2117	8204	2937
	Lysophospholipid receptor	LPAR5	202	21	42	5096	5311	21826	4454	3400	2662	2591	4430	3798
		LPAR6	232	38	66	11368	9222	19940	3599	3276	9451	8748	15106	18231
	P2Y receptor	P2RY12	1050	1	3	4949	22464		704	184	8274	9272	23102	20329
		P2RY13	253	1	5	2487	8282	40696	735	756	5488	4518	5786	6253
	Platelet-activating factor receptor	PTAFR	116	116	37	14233	11427	49899	20366	11692	4132	4410	4404	4745
	Prostanoid receptor	PTGER4	34	39	37	311	121	276	1583	1144	6769	7984	783	1628
Adhesion	G	ADGRG1	477	7	10	9485	11692	43760	4	17	12277	5267	20512	10089
Gα protein	alpha i	GNAI2	285	410	423	39251	23304	29388	31371	18922	7050	7402	6785	7064
		GNAI3	21	22	25	8743	5210	5650	6868	6046	1969	2081	1419	1404
	alpha q	GNAQ	32	21	18	1142	253	599	573	452	2680	2808	2937	2992
		GNA11	7	7	13	126	47	90	137	117	479	407	381	615
		GNA15	36	63	52	3761	2210	3504	3203	3741	1385	1691	915	776
	alpha s	GNAS	426	413	472	6137	2921	5578	6861	5762	13587	15412	11851	14254
	alpha 12/13	GNA12	18	81	97	248	114	193	638	1062	1494	2388	751	1124
		GNA13	64	41	37	3689	1738	3542	3777	2180	12252	20970	3007	3684
GRKs	0	GRK2	183	88	61	1020	464	981	549	522	6982	6244	7575	7469
Arrestin	β-arrestin	ARRB2	324	255	197	7238	2364	4697	5784	4465	4696	5024	5987	5873

FIGURE 2 | Gene expression of selected GPCRs and GPCR signaling molecules in human microglia. Expression of GPCR and GPCR signaling molecule genes in microglia cultured *ex vivo* for 1 and 7 days (10), in iPSC-derived iMPs transplanted neonatal mouse brains or cultured *in vitro* for 10 and 60 days (13), and in white matter and grey matter microglia from control and MS brains (4). Expression is provided as TPM (10) and gene count (4, 13), respectively. CON, control; WM, white matter; GM, grey matter.

In contrast, both disease-associated microglia and infiltrating monocytes had upregulated expression of *CXCR4*. In disease-associated microglia in surgically resected material of Alzheimer's disease patients, GPCR expression was not altered (16).

The late onset of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and ALS, has triggered interest in the effect of aging on microglia gene expression. A study of aged microglia found a lower expression of the microglia signature genes *GPR183*, *P2RY12*, and *P2RY13* (17).

Expression of GPCR signaling molecule genes in the data sets studied here was quite stable. Separation of microglia from their CNS microenvironment or transfer of iMPs into NSG mouse brains only moderately affected signaling molecule gene expression (**Figure 2**). However, white matter microglia more abundantly expressed *GNA13* as compared to grey mater microglia. GPCR signaling molecule genes expression was not

altered in normal-appearing or lesional MS microglia from either white or grey matter (**Figure 3C**).

Expression and MS-Associated Upregulation of CXCR4 by Human White Matter Microglia

The presence and MS-associated upregulation of *CXCR4* expression in microglia is of particular interest since Werner et al. recently showed that CXCR4 distinguishes monocytes from microglia in mice (27). To test whether human microglia express CXCR4, we analyzed freshly isolated cells by flow cytometry, shown here for three donors with MS (**Figure 4A**). Expression was detectable, albeit levels were moderate on white matter microglia and low on grey matter microglia (**Figures 4A, B**). On lesional microglia, we noticed a slightly higher expression of CXCR4 as well as lower expression of P2Y₁₂ compared to



microglia from subcortical normal-appearing white matter, the latter in line with Zrzavy et al. (26) (**Figures 4A, C**). Whole tissue gene expression microarray analysis of laser-dissected control white matter and white matter MS lesions (18) further confirmed increased expression of *CXCR4* in the rim of mixed active/ inactive but not inactive lesions (**Figure 4D**).

To test whether expression of CXCR4 on microglia is functional, we studied transwell migration in response to SDF-1 (CXCL12) (14). SDF-1 binds to CXCR4 and CXCR7, the latter however is not expressed by microglia (**Supplementary Table 2**). Of note SDF-1 stimulated chemotaxis of monocytes, white matter and grey matter microglia at levels corresponding with the presence of CXCR4 (**Figure 4E**). We conclude that CXCR4 expression on human microglia is functional.

DISCUSSION

GPCRs constitute an important share of the sensome of eukaryotic cells. By analyzing various RNAseq datasets, we here provide a comprehensive overview of their presence in microglia. We identified 17 GPCR genes that are robustly transcribed in adult human microglia, including the homeostatic core genes *CX3CR1*, *GPR34*, *GPR183*, *P2RY12*, *P2RY13*, and *ADGRG1*, but also *ADORA3*, *ADRB2*, *CCR1*, *C3AR1*, *C5AR1*, *LPAR5*, *LPAR6*, and *PTAFR*. GPCRs genes well expressed in human microglia but hardly found in mouse microglia were *CXCR4*, *FPR1*, and *PTGER4*.

Figure 5 summarizes the findings of this study. As expected, isolated microglia rapidly lost expression of several GPCRs when



FIGURE 4 | Expression of functional CXCR4 in white and grey matter microglia in health and MS. (A) Representative dot plots of CXCR4 expression on paired peripheral CD14⁺ blood monocytes and P2Y₁₂⁺ microglia from corpus callosum white matter and occipital cortex grey matter, as well as P2Y₁₂⁺ microglia from peri-lesional and lesional subcortical WM of three MS brain donors measured by flow cytometry. (B) Quantification of CXCR4 expression (percentage of positive cells and geoMFI) on monocytes, WM microglia of n=11 brain donors (3 MS, 8 non-MS; Wilcoxon-signed rank test; ***_P < 0.0005). (C) Quantification of CXCR4 and P2Y₁₂ expression on microglia from peri-lesional and lesional WM of three MS brain donors. (D) Quantification of tissue gene expression of *CXCR4* in control as well as peri-lesional and lesional WM form mixed active/inactive and inactive MS lesions (18) (Wilcoxon-signed rank test; *** p < 0.05). (E) Quantification of transwell migration of monocytes, white matter microglia, and grey matter microglia in response to the CXCR4 ligand SDF-1 of n=4 brain donors (left panel). Of note, SDF-1-stimulated transwell migration was higher as compared to spontaneous transwell migration in all three cell types (n=1 brain donor; right panel). A donor with a relatively low expression of CXCR4 on monocytes also showed low monocyte transmigration towards SDF-1 (grey arrowhead). mono, monocytes; CC, corpus callosum; WM, white matter; OC, occipital cortex; GM, grey matter; PL, peri-lesional; Les, lesional; mAI, mixed active/inactive; geoMFI, geometric mean fluorescence intensity.

cultured *ex vivo*, which limits the value of *in vitro*-expanded primary cells for functional studies. In contrast, iPSC-derived iMPs had a GPCR expression remarkably similar to primary microglia, which further equalized upon transfer into NSG mouse brains, ectopically providing critical human growth factors building the microglia phenotype. Regional diversity of microglia has been suggested (2), and we indeed found more abundant expression of *CXCR4* and *PTGER4* in white matter as compared to grey matter microglia in two independent studies [(4) and Mizee et al., unpublished data].

Disease-associated microglia in mouse models of AD and ALS downregulate expression of various GPCR genes, including Cx3cr1, P2ry12, P2ry13, and Adgrg1 (14). The data presented here refer to MS, an inflammatory demyelinating and neurodegenerative disease. Bulk primary microglia collected post-mortem from normal-appearing tissue of MS donors showed downregulation of ADGRG1 (4) in grey and white matter. ADGRG1 encodes the adhesion family GPCR GPR56 (28), which is more widely expressed in the CNS and has been linked in neuronal precursors with cortical lamination and in oligodendrocyte precursors with proliferation (29). Abundant presence of GPR56 on human microglia (4) and regulation of synaptic refinement through a mouse GPR56 splicing isoform (30) have been reported only recently. Obviously, ADGRG1 expression not only distinguishes microglia from other macrophages but also fades out in response to minor changes in the microenvironment, stressing its value as indicator of microglia homeostasis.

In biopsies of active lesions in early cases of MS, diseasesassociated microglia subsets showed the expected general downregulation of GPCR genes associated with microglia homeostasis. Single-cell mass cytometry indeed confirmed the appearance of active MS lesion-enriched clusters with a downregulated surface expression of P2Y₁₂, CX3CR1, and GPR56 (31).

The distribution of the chemokine receptor CXCR4 is of particular interest. CXCR4 binds CXCL12 (SDF-1), which is expressed by the brain vasculature and upregulated in MS lesions (32). Werner et al. recently reported that CXCR4 distinguishes brain-infiltrating monocytes from resident microglia in mice (27). We here demonstrate that human microglia from white and – to a lesser extent – grey matter express CXCR4. Transmigration towards SDF-1 confirmed the relevance of the presence of CXCR4 on microglia. Expression of CXCR4 by both microglia and infiltrating monocytes and upregulation by small subset of MS-associated lesional microglia (15) makes this chemokine receptor, involved in immune cell homeostasis and margination (33), a potentially interesting target for therapeutic intervention. Indeed, *Cxcr4* gene ablation reduced monocyte infiltration and response gene expression in experimental stroke in mice (27).

When testing the expression of genes encoding signaling molecules downstream of GPCRs, in particular G α proteins, GRKs, and β -arrestin (6), we found robust expression of *GNA12, GNAS, GNA13, GRK2*, and *ARRB2*. Further, mice, but not human, abundantly expressed *Gna15*. Expression of these genes did not depend on the specific microenvironment of

			In vitro culture	iMDc	GM vs			Gi/	Gq/		G12/		
Family	Subfamily						1 NAGM	GM lesion	Go	G11	Gs	G12/ G13	Drugs
Rhodopsin	Adenosine receptors	ADORA3	\checkmark						٠				\checkmark
	Adrenoceptors	ADRB2	\checkmark	\uparrow							٠		\checkmark
	Chemokine receptors	CCR1							٠				
		CXCR4	\checkmark		\checkmark		\uparrow	\uparrow	٠				\checkmark
		CX3CR1	\checkmark	\uparrow	\uparrow			\checkmark	٠				
	Orphan receptors	GPR34	\checkmark	\uparrow					٠				
		GPR183		\uparrow	\checkmark				٠				
	Complement peptide receptors	C3AR1											
		C5AR1			\checkmark				٠				
	Formylpeptide receptors	FPR1		\uparrow	\uparrow		\checkmark		٠				
	Lysophospholipid (LPA) receptors	LPAR5	\checkmark	\uparrow						•		٠	
		LPAR6	\checkmark						٠	•		۲	
	P2Y receptors	P2RY12	\checkmark	\uparrow	\uparrow			\checkmark	٠				\checkmark
		P2RY13	\checkmark	\uparrow				\checkmark	٠				
	Platelet-activating factor receptor	PTAFR		\uparrow					٠	•			
	Prostanoid receptors	PTGER4			\checkmark		\uparrow				٠		\checkmark
Adhesion	G	ADGRG1	\checkmark	\uparrow		\checkmark	\checkmark	\checkmark		٠		٠	
G protein	Alpha 12/13	GNA13			\checkmark								

FIGURE 5 | Tabular summary of human microglia GPCR gene regulation, signaling, and drug availability. See Discussion for details. Arrows indicate the direction of regulation. Colored dots indicate prevalence of signaling of GPCRs through the respective G proteins (red = high; light red = medium) and abundance of gene expression of the G proteins in microglia (large dots = high; small dots = low). WM, white matter; GM, grey matter; NAGM, normal-appearing grey matter; NAWM, normal-appearing white matter.

microglia and was found at similar levels in other macrophages. $G\alpha_s$ -coupled receptors activate adenvlate cyclase, leading to cAMP accumulation. While GNAS transcripts were abundant in microglia, only two highly expressed GPCRs primarily couple to this Ga subunit (ADRB2, PTGER4) suggesting rather limited augmentation of cAMP levels in microglia through GPCR signaling. $G\alpha_i$ -coupled receptors inhibit the cAMP-dependent pathway by inhibiting adenylyl cyclase activity. Our data indicate that $G\alpha_{i}$, the preferred $G\alpha$ subunit of 12 of the 17 abundant microglia GPCRs, is well expressed in microglia, implying inhibition of cAMP-dependent protein kinase (PKA). $G\alpha_{12/13}$ coupled receptors activate the small GTPase RhoA. We found GNA13 abundantly transcribed in white but not grey matter, which explains why initial studies of cortical microglia reported dim expression (10). Finally, $G\alpha_q$ -coupled receptors activate phospholipase C to increase intracellular calcium concentration as well as activate protein kinase C, which results in Raf kinase activation of the MAPK pathway. GNAQ transcript levels were generally low, suggesting that LPAR5, LPAR6, and GPR56, which can engage $G\alpha_{12/13}$ as well as $G\alpha_q,$ may rather control cell cytoskeleton remodeling and thus regulate microglia migration. Yet, in particular for GPR56, molecular mechanisms additional to G protein signaling may apply (28, 34).

GPCRs are known for their excellent drugability. A survey at DrugBank (https://www.drugbank.ca/) revealed approved drugs against at least five highly expressed microglia GPCRs with indications covering, amongst others, conditions of the lungs (ADORA3, ADRB2), eye (ADRB2), blood (CXCR4, $P2Y_{12}$), heart ($P2Y_{12}$), and uterus (PTGER4). Moreover, rodent models suggest efficacy of CXCR4 targeting in the treatment of stroke and glioma (35). Studying the effects of small molecules, penetrating the bloodbrain barrier, on microglia *in vitro* and *in vivo* may disclose novel opportunities for the treatment of brain diseases in which microglia emerge as central players, including neurodevelopmental disorders (e.g., autism), neurodegenerative and -inflammatory conditions (e.g., Alzheimer's disease and MS), and chronic pain (1).

In summary, we here describe the GPCR repertoire of human microglia based on publicly available bulk and single-cell RNAseq data. GPCRs that belong to the core signature of microglia are abundantly expressed under homeostatic and rapidly downregulated under non-homeostatic conditions, making them interesting models for studying microenvironmental factors that shape microglia identity during brain development and disease. Datasets of microglia from brain donors with neurological diseases only lately became available and require further investigation. This in particular holds true as drugs targeting different highly

REFERENCES

- Salter MW, Stevens B. Microglia Emerge as Central Players in Brain Disease. Nat Med (2017) 23:1018–27. doi: 10.1038/nm.4397
- Prinz M, Jung S, Priller J. Microglia Biology: One Century of Evolving Concepts. Cell (2019) 179:292–311. doi: 10.1016/j.cell.2019.08.053
- Crotti A, Ransohoff RM. Microglial Physiology and Pathophysiology: Insights From Genome-wide Transcriptional Profiling. *Immunity* (2016) 44:505–15. doi: 10.1016/j.immuni.2016.02.013
- 4. van der Poel M, Ulas T, Mizee MR, Hsiao CC, Miedema SSM, Adelia, et al. Transcriptional Profiling of Human Microglia Reveals Grey–White Matter

expressed microglia GPCRs have been developed, implying their potential application for CNS diseases in which microglia figurate.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi. nlm.nih.gov/ (accessible under accession code GEO: GSE52564, GSE98969, GSE99074, GSE108000, GSE111972, GSE124335, GSE128855, GSE134707, GSE139194), https://www.synapse.org/#!Synapse:syn21438358 and http://shiny.maths.usyd.edu. au/Ellis/MicrogliaPlots/.

ETHICS STATEMENT

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

C-CH and RS extracted and analyzed data. C-CH, RS, MP, JS, IH, and JH designed research and interpreted results. C-CH and JH wrote the paper. All authors contributed to the article and approved the submitted version.

FUNDING

The German Research Foundation (FOR 2149 – JH), the Berta-Ottenstein-Programme for Clinical Scientists (RS), the MS Research Foundation (MS 13-830 – IH/JH), and the Nationaal MS Fonds (OZ2018-003 – JS) funded this research.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021. 674189/full#supplementary-material

Heterogeneity and Multiple Sclerosis-Associated Changes. Nat Commun (2019) 10:1139. doi: 10.1038/s41467-019-08976-7

- Hauser AS, Attwood MM, Rask-Andersen M, Schiöth HB, Gloriam DE. Trends in GPCR Drug Discovery: New Agents, Targets and Indications. *Nat Rev Drug Discov* (2017) 16:829–42. doi: 10.1038/nrd.2017.178
- Pierce KL, Premont RT, Lefkowitz RJ. Seven-Transmembrane Receptors. Nat Rev Mol Cell Biol (2002) 3:639–50. doi: 10.1038/nrm908
- Li Q, Barres BA. Microglia and Macrophages in Brain Homeostasis and Disease. Nat Rev Immunol (2018) 18:225–42. doi: 10.1038/nri.2017.125
- Geirsdottir L, David E, Keren-Shaul H, Weiner A, Bohlen SC, Neuber J, et al. Cross-Species Single-Cell Analysis Reveals Divergence of the Primate

Microglia Program. Cell (2019) 179:1609-22.e16. doi: 10.1016/ j.cell.2019.11.010

- Galatro TF, Holtman IR, Lerario AM, Vainchtein ID, Brouwer N, Sola PR, et al. Transcriptomic Analysis of Purified Human Cortical Microglia Reveals Age-Associated Changes. *Nat Neurosci* (2017) 20:1162–71. doi: 10.1038/nn.4597
- Gosselin D, Skola D, Coufal NG, Holtman IR, Schlachetzki JCM, Sajti E, et al. An Environment-Dependent Transcriptional Network Specifies Human Microglia Identity. *Science* (2017) 356:1248–59. doi: 10.1126/science.aal3222
- Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S, et al. An RNA-sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex. J Neurosci (2014) 34:11929–47. doi: 10.1523/JNEUROSCI.1860-14.2014
- Van Hove H, Martens L, Scheyltjens I, De Vlaminck K, Pombo Antunes AR, De Prijck S, et al. A Single-Cell Atlas of Mouse Brain Macrophages Reveals Unique Transcriptional Identities Shaped by Ontogeny and Tissue Environment. *Nat Neurosci* (2019) 22:1021–35. doi: 10.1038/s41593-019-0393-4
- Svoboda DS, Barrasa MI, Shu J, Rietjens R, Zhang S, Mitalipova M, et al. Human iPSC-derived Microglia Assume a Primary Microglia-Like State After Transplantation Into the Neonatal Mouse Brain. *Proc Natl Acad Sci USA* (2019) 116:25293–303. doi: 10.1073/pnas.1913541116
- Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A Unique Microglia Type Associated With Restricting Development of Alzheimer's Disease. *Cell* (2017) 169:1276–1290.e17. doi: 10.1016/j.cell.2017.05.018
- Masuda T, Sankowski R, Staszewski O, Böttcher C, Amann L, Sagar, et al. Spatial and Temporal Heterogeneity of Mouse and Human Microglia At Single-Cell Resolution. *Nature* (2019) 566:388–92. doi: 10.1038/s41586-019-0924-x
- Olah M, Menon V, Habib N, Taga MF, Ma Y, Yung CJ, et al. Single Cell RNA Sequencing of Human Microglia Uncovers a Subset Associated With Alzheimer's Disease. Nat Commun (2020) 11:6129. doi: 10.1038/s41467-020-19737-2
- Olah M, Patrick E, Villani AC, Xu J, White CC, Ryan KJ, et al. A Transcriptomic Atlas of Aged Human Microglia. *Nat Commun* (2018) 9:539. doi: 10.1038/s41467-018-02926-5
- Hendrickx DAE, van Scheppingen J, van der Poel M, Bossers K, Schuurman KG, van Eden CG, et al. Gene Expression Profiling of Multiple Sclerosis Pathology Identifies Early Patterns of Demyelination Surrounding Chronic Active Lesions. *Front Immunol* (2017) 8:1810. doi: 10.3389/fimmu.2017.01810
- Mizee MR, Miedema SSM, van der Poel M, Adelia, Schuurman KG, van Strien ME, et al. Isolation of Primary Microglia From the Human Post-Mortem Brain: Effects of Ante- and Post-Mortem Variables. *Acta Neuropathol Commun* (2017) 5:16. doi: 10.1186/s40478-017-0418-8
- Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Mathie A, Peters JA, et al. The CONCISE Guide TO Pharmacology 2019/20: G Protein-Coupled Receptors. Br J Pharmacol (2019) 176:S21–141. doi: 10.1111/bph.14748
- Schiöth HB, Lagerström MC. Structural Diversity of G Proteincoupled Receptors and Significance for Drug Discovery. *Nat Rev Drug Discov* (2008) 7:339–57. doi: 10.1038/nrd2518
- Hamann J, Koning N, Pouwels W, Ulfman LH, van Eijk M, Stacey M, et al. EMR1, the Human Homolog of F4/80, is an Eosinophil-Specific Receptor. *Eur J Immunol* (2007) 37:2797–802. doi: 10.1002/eji.200737553
- Lin HH, Hsiao CC, Pabst C, Hébert J, Schöneberg T, Hamann J. Adhesion GPCRs in Regulating Immune Responses and Inflammation. Adv Immunol (2017) 136:163–201. doi: 10.1016/bs.ai.2017.05.005

- 24. Visser L, De Vos AF, Hamann J, Melief MJ, Van Meurs M, Van Lier RAW, et al. Expression of the EGF-TM7 Receptor CD97 and its Ligand CD55 (DAF) in Multiple Sclerosis. J Neuroimmunol (2002) 132:156–63. doi: 10.1016/ S0165-5728(02)00306-5
- Hsiao CC, Van Der Poel M, Van Ham TJ, Hamann J. Macrophages do Not Express the Phagocytic Receptor BAI1/ADGRB1. Front Immunol (2019) 10:962. doi: 10.3389/fimmu.2019.00962
- Zrzavy T, Hametner S, Wimmer I, Butovsky O, Weiner HL, Lassmann H. Loss of "Homeostatic" Microglia and Patterns of Their Activation in Active Multiple Sclerosis. *Brain* (2017) 140:1900–13. doi: 10.1093/brain/awx113
- Werner Y, Mass E, Ashok Kumar P, Ulas T, Händler K, Horne A, et al. Cxcr4 Distinguishes HSC-derived Monocytes From Microglia and Reveals Monocyte Immune Responses to Experimental Stroke. *Nat Neurosci* (2020) 23:351–62. doi: 10.1038/s41593-020-0585-y
- Hamann J, Aust G, Araç D, Engel FB, Formstone C, Fredriksson R, et al. International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G Protein-Coupled Receptors. *Pharmacol Rev* (2015) 67:338–67. doi: 10.1124/ pr.114.009647
- Langenhan T, Piao X, Monk KR. Adhesion G Protein-Coupled Receptors in Nervous System Development and Disease. *Nat Rev Neurosci* (2016) 17:550– 61. doi: 10.1038/nrn.2016.86
- Li T, Chiou B, Gilman CK, Luo R, Koshi T, Yu D, et al. A Splicing Isoform of GPR56 Mediates Microglial Synaptic Refinement Via Phosphatidylserine Binding. *EMBO J* (2020) 39:e104136. doi: 10.15252/embj.2019104136
- Böttcher C, Van Der Poel M, Fernández-Zapata C, Schlickeiser S, Leman JKH, Hsiao CC, et al. Single-Cell Mass Cytometry Reveals Complex Myeloid Cell Composition in Active Lesions of Progressive Multiple Sclerosis. Acta Neuropathol Commun (2020) 8:136. doi: 10.1186/s40478-020-01010-8
- 32. Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisäkk P, Ransohoff RM, et al. Chemokines in Multiple Sclerosis: CXCL12 and CXCL13 Up-Regulation is Differentially Linked to CNS Immune Cell Recruitment. *Brain* (2006) 129:200–11. doi: 10.1093/brain/awh680
- Nagasawa T. CXC Chemokine Ligand 12 (CXCL12) and its Receptor CXCR4. J Mol Med (2014) 92:433–9. doi: 10.1007/s00109-014-1123-8
- 34. Langenhan T, Aust G, Hamann J. Sticky Signaling Adhesion Class G Protein-Coupled Receptors Take the Stage. Sci Signal (2013) 6:re3. doi: 10.1126/scisignal.2003825
- 35. Tahirovic YA, Pelly S, Jecs E, Miller EJ, Sharma SK, Liotta DC, et al. Small Molecule and Peptide-Based CXCR4 Modulators as Therapeutic Agents. A Patent Review for the Period From 2010 to 2018. *Expert Opin Ther Pat* (2020) 30:87–101. doi: 10.1080/13543776.2020.1707186

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Hsiao, Sankowski, Prinz, Smolders, Huitinga and Hamann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.